Go Pro
→ After KDA, PRE, and OCEAN—this is the one (From Crypto 101 Media) (Ad)tc pixel
OTCMKTS:SEOVF

Sernova Biotherapeutics Q4 2025 Earnings Report

Sernova Biotherapeutics logo
$0.08 +0.01 (+9.88%)
As of 01:31 PM Eastern
ProfileEarnings History

Sernova Biotherapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sernova Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sernova Biotherapeutics Announcement Details

Quarter
Q4 2025
Date
12/19/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Sernova Biotherapeutics' next earnings date is estimated for Thursday, September 10, 2026, based on past reporting schedules.

Conference Call Resources

Sernova Biotherapeutics Earnings Headlines

Sernova Biotherapeutics Inc SEOVF
May 14, 2026  |  morningstar.comM
Sernova Biotherapeutics: Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to ...
March 4, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67852946-sernova-biotherapeutics-sernova-biotherapeutics-strengthens-balance-sheet-with-dollar-7-1-million-in-financings-plus-net-retirement-of-a-cumulative-dollar-17-mil-296.htm
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel
August 14 at 1:00 AM  |  Porter & Company (Ad)
Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts
November 13, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/sernova-biotherapeutics-closes-first-tranche-120000926.html
Sernova Biotherapeutics Announces Collaboration with Eledon ...
July 11, 2025  |  morningstar.comM
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
July 9, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/09/3112555/0/en/sernova-biotherapeutics-announces-collaboration-with-eledon-pharmaceuticals-to-advance-a-potential-functional-cure-for-type-1-diabetes.html
See More Sernova Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sernova Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sernova Biotherapeutics and other key companies, straight to your email.

About Sernova Biotherapeutics

Sernova Biotherapeutics (OTCMKTS:SEOVF) is a clinical‐stage biotechnology company focused on developing and commercializing cell‐based therapeutic technologies for patients with chronic and life‐threatening diseases. Headquartered in London, Ontario, Canada, the firm is advancing an implantable device platform designed to support the long-term survival and function of therapeutic cells. The company’s lead product candidate, known as the Cell Pouch System, is engineered to create a vascularized environment in which transplanted cells can thrive, with an initial emphasis on treating patients with type 1 diabetes.

In its core program, Sernova has initiated a Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch System in individuals with type 1 diabetes who require islet cell transplantation. Beyond diabetes, the company is exploring broader applications of its delivery platform, including therapies for hemophilia and other endocrine and metabolic disorders. Preclinical studies have demonstrated the ability of the Cell Pouch to promote cell engraftment and function, positioning Sernova’s technology as a potential alternative to conventional chronic drug administration.

Founded in 2008 and formerly known as Sernova Corp, the company rebranded as Sernova Biotherapeutics in late 2023 to better reflect its evolving pipeline. Sernova conducts its clinical activities across North America and Europe, collaborating with academic and clinical research centers to advance its trials. Leading the organization is Dr. Philip A. Toleikis, Sernova’s founder, president and chief executive officer, who brings more than two decades of experience in regenerative medicine and cell‐based therapy development.

View Sernova Biotherapeutics Profile
Earnings Tools